U.S. Markets closed

AMAG Pharmaceuticals, Inc. (AMAG)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
19.30+0.20 (+1.05%)
At close: 4:00PM EDT
People also watch
ACORALNYAKRXANACMNTA
  • Down 5% on very low volume - smells like hedgies trying to get folks to sell to start covering some short positions... I'm anticipating a healthy swing in earnings this qtr.
  • Who says AMAG isn't poised for potentially massive upward movement? I started receiving notifications from awe*some*stocks the other week and so far they have presented interesting new trade ideas.
  • Just looking for survivors. Those remaining may want to purchase insurance for what could be a rough ascent...
  • IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • Monster MicroCaps SPECIAL ALERT to AMAG shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market.
    https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html

    NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
    This completes the Company's payoff of $11 million in principal amount of bonds, plus associated interest and forbearance fees, over the period from March through June of this year in accordance with an installment payment agreement with the bondhold
    finance.yahoo.com
  • Damn I just bought at $16.30, it'll probably reach a new low today...
  • AMAG reached a new 52 Week Low at 16.00
  • They don't have funds to cover anymore expenses... Soon will be offering more shares to public or worse to BANKRUPTCY :(((
  • Is this a good time to get in or will it be dropping some more?
  • Bearish
  • AMAG reached a new 52 Week Low at 16.25
  • AMAG reached a new 52 Week Low at 16.40
  • AMAG reached a new 52 Week Low at 16.58
  • 2017-5-31 AMAG traded around 1.4 million shares right at the close today. Does anyone have an explanation of this unusual trade or what we might expect in the next couple of days?
  • Was told this morning by healthcare provider that there may be a data breach/loss at AMAG.
  • AMAG reached a new 52 Week Low at 17.50
  • Why?
  • AMAG reached a new 52 Week Low at 17.70
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio.

    • BioLargo’s 10Q states their Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence in first half of 2018
    • Sales and or licensing agreement/s could be very significant
    • Company is now commercializing several other disruptive products in large markets

    http://www.clyramedical.com

    https://www.sec.gov/Archives/edgar/data/880242/000143774917009469/blgo20170331_10q.htm

    Clyra Medical | Make Life Better
    www.clyramedical.com
  • At 18.50 this stock is a good value to buy in now wish I was a little more patient and had waited but I went all in at 20.95.